Alpha Cognition IncCanadian Securities Exchange:ACOGView on OTCQB
- LAST PRICE0.6500
- TODAY'S CHANGE (%)-0.0300 (-4.4118%)
- Bid / Lots0.6100/ 4
- Ask / Lots0.6800/ 4
- Open / Previous Close0.6600 / 0.6800
- Day Range
- 52 Week Range
- Volume57,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACOG |
|---|---|---|
| 09:36 ET | 13000 | 0.65 |
| 09:39 ET | 9500 | 0.65 |
| 09:56 ET | 5000 | 0.65 |
| 01:26 ET | 29500 | 0.65 |
Apr 3, 2024
Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update, from 10:08PM ET on Wednesday Apr 03, 2024 by Dow Jones
10:08PM ET on Wednesday Apr 03, 2024 by Dow JonesPress Release: Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update, from 10:08PM ET on Wednesday Apr 03, 2024 by Dow Jones
10:08PM ET on Wednesday Apr 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alpha Cognition Inc | 97.5M | -3.4x | --- |
NervGen Pharma Corp | 147.5M | -5.6x | --- |
Zentek Ltd | 149.2M | -12.4x | --- |
Arch Biopartners Inc | 119.4M | -60.9x | --- |
Oncolytics Biotech Inc | 110.9M | -3.5x | --- |
Cardiol Therapeutics Inc | 167.3M | -5.6x | --- |
Company Information
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.
Contact Information
- Headquarters
- c/o 1200 - 750 West Pender StreetVancouver, BC, Canada V6C 2T8
- Phone
- 604-564-9244
- Fax
- ---
Executives
- Independent Chairman of the Board
- Len Mertz
- Chief Executive Officer, Director
- Michael Mcfadden
- Chief Financial Officer
- Donald Kalkofen
- Chief Commercial Officer
- Lauren D'Angelo
- Director, Corporate Secretary
- Kenneth Cawkell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $97.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 149.9M |
Alpha Cognition Inc does not pay a dividend. | |
Beta | 3.42 |
EPS | $-0.19 |
Book Value | $-0.05 |
P/E Ratio | -3.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
